Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Nitrous Oxide as Treatment for Major Depression - a Pilot Study


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02139540

Organisation Name: Washington University School of Medicine

Overal Status: Completed

Start Date: November 2012

Last Update: January 27, 2020

Lead Sponsor: Washington University School of Medicine

Brief Summary: Major depressive disorder (MDD) is a global medical problem with significant shortcomings in current therapy. Chief among these is the delay between initiation of pharmacologic therapy and clinical improvement in symptoms. Recently ketamine, an NDMA-receptor antagonist has been shown to rapidly and effectively reverse the symptoms of MDD. Nitrous oxide, another NMDA-receptor antagonist, may produce the same effect with a cleaner side-effect profile and perhaps without the need for intravenous access and anesthesia personnel. Therefore, we propose conducting a pilot randomized placebo controlled double-blind crossover study in which patients will receive up to 50% nitrous oxide in oxygen or up to 50% oxygen in air for a period of one hour in addition to standard medical therapy. Depression severity will be assessed by a blinded observer pre-treatment, 30 minutes and 2 hours post treatment using the Hamilton depression rating scale.

Conditions:
  • Depression
  • Major Depressive Disorder


Total execution time in seconds: 0.3389310836792